These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

302 related items for PubMed ID: 16377036

  • 1. Immunogenicity and protective efficacy of Escherichia coli expressed Plasmodium falciparum merozoite surface protein-1(42) using human compatible adjuvants.
    Sachdeva S, Mohmmed A, Dasaradhi PV, Crabb BS, Katyal A, Malhotra P, Chauhan VS.
    Vaccine; 2006 Mar 15; 24(12):2007-16. PubMed ID: 16377036
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Immunogenicity of a recombinant malaria vaccine candidate, domain I+II of AMA-1 ectodomain, from Indian P. falciparum alleles.
    Lalitha PV, Biswas S, Pillai CR, Saxena RK.
    Vaccine; 2008 Aug 18; 26(35):4526-35. PubMed ID: 18590786
    [Abstract] [Full Text] [Related]

  • 6. Immunogenicity and in vitro protective efficacy of a polyepitope Plasmodium falciparum candidate vaccine constructed by epitope shuffling.
    Cai Q, Peng G, Bu L, Lin Y, Zhang L, Lustigmen S, Wang H.
    Vaccine; 2007 Jul 09; 25(28):5155-65. PubMed ID: 17548134
    [Abstract] [Full Text] [Related]

  • 7. Plasmodium falciparum merozoite surface protein 1 (MSP-1)-MSP-3 chimeric protein: immunogenicity determined with human-compatible adjuvants and induction of protective immune response.
    Mazumdar S, Mukherjee P, Yazdani SS, Jain SK, Mohmmed A, Chauhan VS.
    Infect Immun; 2010 Feb 09; 78(2):872-83. PubMed ID: 19933832
    [Abstract] [Full Text] [Related]

  • 8. Immunogenicity of a chimeric Plasmodium falciparum merozoite surface protein vaccine in Aotus monkeys.
    Burns JM, Miura K, Sullivan J, Long CA, Barnwell JW.
    Malar J; 2016 Mar 15; 15():159. PubMed ID: 26975721
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Immunogenicity of a recombinant malaria vaccine based on receptor binding domain of Plasmodium falciparum EBA-175.
    Pattnaik P, Shakri AR, Singh S, Goel S, Mukherjee P, Chitnis CE.
    Vaccine; 2007 Jan 15; 25(5):806-13. PubMed ID: 17045706
    [Abstract] [Full Text] [Related]

  • 12. Antibodies to the conserved C-terminal domain of the Plasmodium falciparum merozoite surface protein 1 and to the merozoite extract and their relationship with in vitro inhibitory antibodies and protection against clinical malaria in a Senegalese village.
    Perraut R, Marrama L, Diouf B, Sokhna C, Tall A, Nabeth P, Trape JF, Longacre S, Mercereau-Puijalon O.
    J Infect Dis; 2005 Jan 15; 191(2):264-71. PubMed ID: 15609237
    [Abstract] [Full Text] [Related]

  • 13. Production and preclinical evaluation of Plasmodium falciparum MSP-119 and MSP-311 chimeric protein, PfMSP-Fu24.
    Gupta PK, Mukherjee P, Dhawan S, Pandey AK, Mazumdar S, Gaur D, Jain SK, Chauhan VS.
    Clin Vaccine Immunol; 2014 Jun 15; 21(6):886-97. PubMed ID: 24789797
    [Abstract] [Full Text] [Related]

  • 14. IgG subclass antibodies to three variants of Plasmodium falciparum merozoite surface protein-1 (PfMSP-1(19)) in an area with unstable malaria transmission in Iran.
    Mehrizi AA, Asgharpour S, Salmanian AH, Djadid ND, Zakeri S.
    Acta Trop; 2011 Aug 15; 119(2-3):84-90. PubMed ID: 21609709
    [Abstract] [Full Text] [Related]

  • 15. Long-lasting protective immune response to the 19-kilodalton carboxy-terminal fragment of Plasmodium yoelii merozoite surface protein 1 in mice.
    Jeamwattanalert P, Mahakunkijcharoen Y, Kittigul L, Mahannop P, Pichyangkul S, Hirunpetcharat C.
    Clin Vaccine Immunol; 2007 Apr 15; 14(4):342-7. PubMed ID: 17314232
    [Abstract] [Full Text] [Related]

  • 16. Immune responses elicited by co-immunization of Plasmodium vivax and P. falciparum MSP-1 using prime-boost immunization strategies.
    Mehrizi AA, Zakeri S, Rafati S, Salmanian AH, Djadid ND.
    Parasite Immunol; 2011 Nov 15; 33(11):594-608. PubMed ID: 21883290
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Immunogenicity of the C-terminal 19-kDa fragment of the Plasmodium falciparum merozoite surface protein 1 (MSP1), YMSP1(19) expressed in S. cerevisiae.
    Hui GS, Gosnell WL, Case SE, Hashiro C, Nikaido C, Hashimoto A, Kaslow DC.
    J Immunol; 1994 Sep 15; 153(6):2544-53. PubMed ID: 8077664
    [Abstract] [Full Text] [Related]

  • 19. Immunization of Saimiri sciureus monkeys with Plasmodium falciparum merozoite surface protein-3 and glutamate-rich protein suggests that protection is related to antibody levels.
    Carvalho LJ, Oliveira SG, Theisen M, Alves FA, Andrade MC, Zanini GM, Brígido MC, Oeuvray C, Póvoa MM, Muniz JA, Druilhe P, Daniel-Ribeiro CT.
    Scand J Immunol; 2004 Apr 15; 59(4):363-72. PubMed ID: 15049780
    [Abstract] [Full Text] [Related]

  • 20. A Plasmodium falciparum GLURP-MSP3 chimeric protein; expression in Lactococcus lactis, immunogenicity and induction of biologically active antibodies.
    Theisen M, Soe S, Brunstedt K, Follmann F, Bredmose L, Israelsen H, Madsen SM, Druilhe P.
    Vaccine; 2004 Mar 12; 22(9-10):1188-98. PubMed ID: 15003647
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.